Evidence map›Paper›PMID 34981812›Full record

ArticleInternational journal of oncology2022

Functional assessment of miR‑1291 in colon cancer cells.

Jiaqi Wang, Yuhki Yokoyama, Haruka Hirose, Yuki Shimomura, Saki Bonkobara, Hiroaki Itakura, Shihori Kouda, Yoshihiro Morimoto, Kazumasa Minami, Hidekazu Takahashi and 8 more

Open access · hybridAbstract read
In one paragraph

Article in International journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Pleiotropic effects of DCLK1 in cancer and cancer stem cells.Frontiers in molecular biosciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Jiaqi WangDepartment of Molecular Pathology, Division of Health Sciences, Osaka University, Suita, Osaka 565‑0871, Japan.
Yuhki YokoyamaDepartment of Molecular Pathology, Division of Health Sciences, Osaka University, Suita, Osaka 565‑0871, Japan.
Haruka HiroseDepartment of Molecular Pathology, Division of Health Sciences, Osaka University, Suita, Osaka 565‑0871, Japan.
Yuki ShimomuraDepartment of Molecular Pathology, Division of Health Sciences, Osaka University, Suita, Osaka 565‑0871, Japan.
Saki BonkobaraDepartment of Molecular Pathology, Division of Health Sciences, Osaka University, Suita, Osaka 565‑0871, Japan.
Hiroaki ItakuraDepartment of Surgery and Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka 565‑0871, Japan.
Shihori KoudaDepartment of Molecular Pathology, Division of Health Sciences, Osaka University, Suita, Osaka 565‑0871, Japan.
Yoshihiro MorimotoDepartment of Surgery and Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka 565‑0871, Japan.
Kazumasa MinamiDepartment of Radiation Oncology, Graduate School of Medicine, Osaka University, Suita, Osaka 565‑0871, Japan.
Hidekazu TakahashiDepartment of Surgery and Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka 565‑0871, Japan.
Satoshi ShibataDepartment of Molecular Pathology, Division of Health Sciences, Osaka University, Suita, Osaka 565‑0871, Japan.
Shogo KobayashiDepartment of Surgery and Gastroenterological Surgery, Graduate School of Medicine, Osaka University,Suita, Osaka 565‑0871, Japan.
Mamoru UemuraDepartment of Surgery and Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka 565‑0871, Japan.
Susumu TanakaFirst Department of Oral and Maxillofacial Surgery, Graduate School of Dentistry, Osaka University, Suita, Osaka 565‑0871, Japan.
Xin WuDepartment of Molecular Pathology, Division of Health Sciences, Osaka University, Suita, Osaka 565‑0871, Japan.
Shinji TanakaDepartment of Molecular Oncology, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo 113‑8510, Japan.
Masaki MoriTokai University, Graduate School of Medicine, Isehara, Kanagawa 259‑1193, Japan.
Hirofumi YamamotoDepartment of Molecular Pathology, Division of Health Sciences, Osaka University, Suita, Osaka 565‑0871, Japan.
Osaka University · JPTokai University · JPTokyo Medical and Dental University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

miR‑1291 exerts an anti‑tumor effect in a subset of human carcinomas, including pancreatic cancer. However, its role in colorectal cancer (CRC) is largely unknown. In the present study, the expression and effect of miR‑1291 in CRC cells was investigated. It was identified that miR‑1291 significantly suppressed the proliferation, invasion, cell mobility and colony formation of CRC cells. Additionally, miR‑1291 induced cell apoptosis. A luciferase reporter assay revealed that miR‑1291 directly bound the 3'‑untranslated region sequence of doublecortin‑like kinase 1 (DCLK1). miR‑1291 also suppressed DCLK1 mRNA and protein expression in HCT116 cells that expressed DCLK1. Furthermore, miR‑1291 suppressed cancer stem cell markers BMI1 and CD133, and inhibited sphere formation. The inhibitory effects on sphere formation, invasion and mobility in HCT116 cells were also explored and verified using DCLK1 siRNAs. Furthermore, miR‑1291 induced CDK inhibitors p21

Indexed as

Cell LineColonic NeoplasmsDoublecortin-Like KinasesHumansMicroRNAsDCLK1 protein, humanDoublecortin-Like KinasesMicroRNAsMIRN1291 microRNA, humancolorectal cancerDCLK1miR‑1291p21CIP1/WAF1p27KIP1

Identifiers

PMID34981812
PMCPMC8759348
OpenAlexW4205205129

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.